Skip to main content
SpringerLink
Log in

Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinson’s disease

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Dopamine transporter (DAT) imaging shows age-related decline of ligand binding in the normal striatum, a decline attributed to regulatory changes. We investigated if similar changes occur in the striatum of Parkinson’s disease (PD) patients, using PET and [18F]FP-CIT, a ligand for DAT.

Methods

We performed [18F]FP-CIT PET in 39 drug-naïve, de novo PD patients (age 56.0 ± 11.6 years, mean ± SD) and 34 healthy control subjects (age 52.3 ± 17.8). Parkinsonism was assessed by UPDRS III and Purdue pegboard. Binding ratios of [18F]FP-CIT were obtained in the putamen and caudate using the occipital cortex as reference.

Results

Mean [18F]FP-CIT binding ratios in PD were 3.76 ± 0.74 (mean ± SD) in the putamen and 6.80 ± 1.05 in the caudate nucleus, significantly smaller than those in the healthy control (9.20 ± 1.38, 8.66 ± 1.12, respectively; p < 0.001 vs. healthy control for both). Regression analysis of [18F]FP-CIT binding ratios on age in healthy subjects showed significant correlations in the putamen (p < 0.001) and caudate nucleus (p < 0.001). Similar analysis in PD patients also showed significant correlations in the putamen (p = 0.015) and caudate nucleus (p = 0.018). The slope of regression in the putamen was −0.061 in the healthy control and −0.017 in PD, with significant differences between the two groups (p = 0.0003). In contrast, the regression slope in the caudate nucleus was −0.040 in the healthy control group, and −0.032 in the PD group with no significant differences between the two groups.

Conclusions

Striatal [18F]FP-CIT binding showed significant age affects in patients with de novo PD after standardization for the severity of disease. The age effects were significantly smaller in PD patients than those in healthy subjects, but only in the putamen, not in the caudate nucleus. Given that age-related attrition of DA neurons is even in normal striatum, the uneven age effects in the parkinsonian striatum are likely to reflect the superimposition of disease-driven compensation on the aging effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol. 1989;26:535–42.

    Article  CAS  PubMed  Google Scholar 

  2. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995;36:1175–81.

    PubMed  Google Scholar 

  3. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.

    CAS  PubMed  Google Scholar 

  4. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson’s disease. Ann Neurol. 1990;28:799–804.

    Article  CAS  PubMed  Google Scholar 

  5. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996;40:873–84.

    Article  CAS  PubMed  Google Scholar 

  6. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760–5.

    CAS  PubMed  Google Scholar 

  7. Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, Sossi V, et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse. 2010;64:146–51.

    Article  CAS  PubMed  Google Scholar 

  8. Zahniser NR, Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology. 2004;47(Suppl 1):80–91.

    Article  CAS  PubMed  Google Scholar 

  9. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol. 2000;47:493–503.

    Article  CAS  PubMed  Google Scholar 

  10. Salvatore MF, Apparsundaram S, Gerhardt GA. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging. 2003;24:1147–54.

    Article  CAS  PubMed  Google Scholar 

  11. Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, et al. [123I]beta-CIT single-photon emission tomography in Parkinson’s disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med. 1997;24:1171–4.

    CAS  PubMed  Google Scholar 

  12. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39:1143–8.

    CAS  PubMed  Google Scholar 

  13. Hornykiewicz O. Biochemical aspects of Parkinson’s disease. Neurology. 1998;51:S2–9.

    Article  CAS  PubMed  Google Scholar 

  14. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol. 1993;50:140–8.

    Article  CAS  PubMed  Google Scholar 

  15. Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853–9.

    Article  PubMed  Google Scholar 

  16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.

    Article  CAS  PubMed  Google Scholar 

  17. Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007;34:345–51.

    Article  CAS  PubMed  Google Scholar 

  18. Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, Moon DH, Oh SJ, Chung SJ, Lee CS. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399–406.

    Article  CAS  PubMed  Google Scholar 

  19. Sun FT, Schriber RA, Greenia JM, He J, Gitcho A, Jagust WJ. Automated template-based PET region of interest analyses in the aging brain. Neuroimage. 2007;34:608–17.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Vingerhoets FJ, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, Cooper S, Calne DB. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med. 1994;35(1):18–24.

    CAS  PubMed  Google Scholar 

  21. Wullner U, Pakzaban P, Brownell AL, Hantraye P, Burns L, Shoup T, et al. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. Exp Neurol. 1994;126:305–9.

    Article  CAS  PubMed  Google Scholar 

  22. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson’s disease. Synapse. 2001;39:101–8.

    Article  CAS  PubMed  Google Scholar 

  23. De La Fuente-Fernandez R, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB, et al. Age and severity of nigrostriatal damage at onset of Parkinson’s disease. Synapse. 2003;47:152–8.

    Article  Google Scholar 

  24. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol. 2011;69:803–10.

    Article  PubMed  Google Scholar 

  25. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson’s disease. Neurology. 1996;47:718–26.

    Article  CAS  PubMed  Google Scholar 

  26. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson’s disease. J Neurochem. 1992;58:642–8.

    Article  CAS  PubMed  Google Scholar 

  27. Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse. 2009;63:282–90.

    Article  CAS  PubMed  Google Scholar 

  28. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16:3507–10.

    CAS  PubMed  Google Scholar 

  29. Afonso-Oramas D, Cruz-Muros I, Barroso-Chinea P, Alvarez de la Rosa D, Castro-Hernandez J, Salas-Hernandez J, et al. The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis. 2010;40:518–30.

    Article  CAS  PubMed  Google Scholar 

  30. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 1997;48:969–77.

    Article  CAS  PubMed  Google Scholar 

  31. Cruz-Muros I, Afonso-Oramas D, Abreu P, Perez-Delgado MM, Rodriguez M, Gonzalez-Hernandez T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol Aging. 2009;30:973–86.

    Article  CAS  PubMed  Google Scholar 

  32. Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson’s disease. Adv Neurol. 2003;91:183–91.

    PubMed  Google Scholar 

  33. Bedard P, Larochelle L, Parent A, Poirier LJ. The nigrostriatal pathway: a correlative study based on neuroanatomical and neurochemical criteria in the cat and the monkey. Exp Neurol. 1969;25:365–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by Grants from the Korean government (MEST) (No. 2010-0020677) through the future based technology development program of the National Research Foundation.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Chong S. Lee & Su-Jeong Kim

  2. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Seung Jun Oh, Hye Ok Kim & Jae Seung Kim

  3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Sung-Cheol Yun

  4. Department of Medicine/Neurology, University of British Columbia, Vancouver, Canada

    Doris Doudet

Authors
  1. Chong S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Su-Jeong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung Jun Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hye Ok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung-Cheol Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Doris Doudet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jae Seung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Seung Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, C.S., Kim, SJ., Oh, S.J. et al. Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinson’s disease. Ann Nucl Med 28, 874–879 (2014). https://doi.org/10.1007/s12149-014-0882-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-014-0882-1

Keywords

Search

Navigation